Skip to main content
. 2017 Apr 5;28(7):1625–1630. doi: 10.1093/annonc/mdx161

Figure 1.

Figure 1.

Schematic of study design. BRCA, breast adenocarcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; UCEC, uterine corpus endometrial carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; COAD, READ; colon and rectal carcinoma; BLCA, bladder urothelial carcinoma; KIRC, kidney renal clear cell carcinoma; OV, ovarian serous carcinoma; AML, acute myeloid leukemia; LC; lung cancer. *Refer to reference 6.